New CMV vaccine enters first human tests – could prevent dangerous infections
NCT ID NCT05089630
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new vaccine against cytomegalovirus (CMV), a common virus that can cause serious problems in newborns and people with weakened immune systems. The study involves 339 healthy adults aged 18 to 50, who will receive different doses of the vaccine or a placebo. The main goal is to check safety and how well the vaccine triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CMV vaccine (recombinant protein with adjuvant)
What this could lead to
If successful, this could lead to a vaccine that prevents cytomegalovirus (CMV) infection, which is especially dangerous for pregnant women and people with weak immune systems.
What could go wrong
This is an early first-in-human trial, so the vaccine may not trigger a strong enough immune response or could cause side effects. It is too soon to know if it will work in the real world.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Lexington, Kentucky, 40536-0084, United States
-
GSK Investigational Site
Dearborn, Michigan, 48127, United States
-
GSK Investigational Site
Springfield, Missouri, 65802, United States
-
GSK Investigational Site
Lincoln, Nebraska, 68510, United States
-
GSK Investigational Site
Omaha, Nebraska, 68134, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89109, United States
-
GSK Investigational Site
Newark, New Jersey, 07103, United States
-
GSK Investigational Site
Secaucus, New Jersey, 07094, United States
-
GSK Investigational Site
New York, New York, 10065, United States
-
GSK Investigational Site
Austin, Texas, 78744-1645, United States
-
GSK Investigational Site
Cedar Park, Texas, 78613, United States
-
GSK Investigational Site
Galveston, Texas, 77573, United States
-
GSK Investigational Site
Puyallup, Washington, 98371, United States
-
GSK Investigational Site
Anaheim, California, 92806, United States
-
GSK Investigational Site
Long Beach, California, 90806, United States
-
GSK Investigational Site
Los Angeles, California, 90017, United States
-
GSK Investigational Site
Hallandale, Florida, 33009, United States
-
GSK Investigational Site
Miami, Florida, 33143, United States